Sofinnova Partners

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

Forth Therapeutics is a biotechnology company specializing in the development of precision treatments for fibrotic diseases. The company employs advanced computational models and machine learning algorithms to integrate single cell and spatial genomics data, enabling it to identify antifibrotic targets with high precision. This approach allows Forth Therapeutics to create detailed maps of fibrotic diseases, accelerating the discovery and development of precision drugs.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Latent Labs is a pioneering AI laboratory specializing in programmable biology. The company develops advanced generative AI models that capture the fundamental principles of biology, empowering healthcare partners to create novel antibodies, optimize existing enzymes, and advance genetic engineering. This enables partners to gain unparalleled control over molecular biology, driving transformative advancements in health and sustainability.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Purespring Therapeutics is an innovative company dedicated to developing gene therapies for kidney diseases, with a strong emphasis on podocytes, the specialized cells in the kidneys. As one of the pioneers in utilizing AAV gene therapy for renal conditions, Purespring aims to address significant unmet medical needs in this challenging area of healthcare. The company has established an in-vivo functional screening platform designed to identify protective factors that could be beneficial across a range of kidney diseases, while also exploring applications for gene therapy in cardiovascular disorders. Through its focused approach, Purespring is positioned to make a meaningful impact in the treatment of renal conditions.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Cure51 is focused on building a comprehensive database of cancer survivors to harness their unique biological characteristics in the pursuit of new cancer therapies. The company develops a clinical and molecular database aimed at expediting drug discovery by analyzing the biology of long-term cancer survivors. This approach allows researchers to identify potential targets for drug development by decoding genetic information from various sources, including biopsies, blood tests, and imaging. By leveraging insights gained from this data, Cure51 aims to contribute to the formulation of innovative treatments for cancer.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

DISCO Pharmaceuticals is a company focused on advancing cancer treatment through its innovative surfaceome mapping platform. This technology enables the identification of proteins and protein communities on the cancer cell surface at a large scale, providing detailed insights that traditional proteomics and genomic methods cannot offer. By unlocking the surfaceome of cancer cells, DISCO Pharmaceuticals aims to facilitate the development of cancer-selective therapies that enhance treatment efficacy while minimizing side effects for patients. The company's approach holds promise for improving patient care by enabling more targeted and effective therapeutic options in oncology.

Qorium is a biotechnology company focused on producing sustainable, cell-cultured collagen-based leather. By utilizing advanced cell culturing and tissue engineering technologies, Qorium aims to minimize the environmental impact associated with traditional leather manufacturing. The company's innovative approach provides a premium alternative to conventional leather, which is often linked to issues such as deforestation and the meat industry. As a result, Qorium offers a viable option for consumers seeking animal-free leather products while promoting sustainability in the fashion and materials industries.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Betteromics is a SaaS platform designed to enhance data analysis in the life sciences industry through advanced AI and computational techniques. The platform operates as a Private SaaS within a Virtual Private Cloud (VPC), facilitating seamless connections across diverse data sources. It offers a centralized and objective source of truth, enabling team members to access reliable information and create accurate descriptions. Founded by seasoned professionals with backgrounds in Google and GRAIL, Betteromics combines expertise from academia, science, and technology to empower users to efficiently collect, process, and analyze complex multi-modal molecular datasets. This capability allows users to make informed decisions more swiftly, ultimately advancing their research and operational goals.

Bon Vivant is a French biotechnology startup founded by Hélène Briand and Stéphane Mac Millan, specializing in the development of plant-based milk alternatives. The company utilizes precision fermentation technology to create non-dairy products that closely mimic the texture and taste of traditional dairy. By cultivating milk proteins in a vegetable culture medium, Bon Vivant aims to provide accessible and pure alternatives to cheese and other dairy items, catering to consumers seeking dairy-free options without compromising on quality.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Werewool is engaged in the development of a biomaterials platform focused on creating biodegradable fibers for sustainable textiles. The company's innovative approach involves designing fibers at the DNA level, allowing for tailored aesthetic and performance properties, such as color, moisture management, and stretch. This technology aims to support the fashion industry in producing apparel that minimizes environmental impact, promoting a more sustainable approach to textile production.

Alia Therapeutics focuses on developing advanced gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools to target and correct inborn genetic errors directly within patients' cells. By utilizing these unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their source, providing healthcare professionals with the means to modify genomes effectively. Additionally, the company emphasizes safe and efficient delivery mechanisms to ensure the targeted treatment of affected cells.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

Nuage Therapeutics is a pharmaceutical company dedicated to developing selective and potent drugs that target intrinsically disordered proteins, which are often associated with challenging medical conditions. The company employs innovative approaches in chemical biology and biomolecular condensation to create selective inhibitors aimed at treating diseases such as castration-resistant prostate cancer. By focusing on these complex and often "undruggable" protein targets, Nuage Therapeutics aims to address significant unmet medical needs and improve patient outcomes through targeted therapeutic solutions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. The company specializes in biocatalysis and a cell-free synthetic biology platform to create sustainable alternatives to conventional materials such as plastics, nylons, and rubbers. EnginZyme's innovative approach focuses on biomanufacturing techniques that promote green chemistry across various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By utilizing patented cell-free technology, EnginZyme aims to replace traditional fossil-based manufacturing, thus facilitating the shift toward environmentally friendly production methods. The company has gained recognition for its contributions to sustainability, being named a Global Cleantech 100 company and recognized as a Technology Pioneer by the World Economic Forum. EnginZyme is supported by a diverse group of investors, reflecting its potential impact on addressing climate change and promoting sustainable practices in manufacturing.

Microphyt specializes in the research, development, production, and marketing of natural algae-based products aimed at enhancing health and wellness. The company focuses on creating bioactive dietary supplements that support weight loss and brain health. Utilizing an industrial-scale supply of microalgae biomass and extracts, Microphyt ensures the preservation of cell integrity while producing commercial quantities of slow-growing or biofilm-forming species. This approach enables the healthcare industry to effectively meet the demands of personal care and food products, positioning Microphyt as a key player in the market for natural health solutions.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

GFBiochemicals is a pioneering company that specializes in the production of levulinic acid directly from biomass on a commercial scale. Founded in 2008 by a group of biobased chemical experts, the company aims to revolutionize the chemicals and biofuels market by replacing petroleum-based products with sustainable alternatives. Through partnerships with the University of Pisa and the Polytechnic University of Milan, GFBiochemicals has developed breakthrough production technologies showcased in their Caserta plant. This plant has been equipped with innovative conversion, recovery, and purification technology to support the company's mission of advancing sustainable and eco-friendly solutions in various market sectors.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in developing bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on producing specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. Utilizing its Dynamic Metabolic Control technology, DMC Biotechnologies aims to enhance the efficiency and sustainability of production processes, reducing both energy consumption and resource use. This innovative approach allows for quicker development timelines and lower costs, supporting a transition towards a more sustainable economy.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Nitrase Therapeutics is a biopharmaceutical platform company focused on developing therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, the company aims to create drugs that may slow or halt the progression of this and other related neurodegenerative conditions. By leveraging its expertise in nitration, Nitrase Therapeutics seeks to explore the therapeutic potential of biochemical modifications of proteins, particularly through the identification of nitro-substrates and their involvement in various diseases. This approach positions the company to potentially expand its platform to address a broader range of medical conditions in the future.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Leucid Bio is a biotechnology company focused on developing innovative cell therapies for patients with refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is guided by a seasoned management team possessing both scientific and commercial expertise. The company has a strong partnership with King's College, granting it exclusive access to a wealth of scientific, clinical, and manufacturing resources, particularly from Dr. Maher and his team of immuno-oncology specialists. By specializing in advanced CAR T-cell therapies, Leucid Bio aims to enhance treatment outcomes and provide durable responses for patients who have limited or no treatment options available.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Protera specializes in the development of functional ingredients for the food industry through protein engineering and artificial intelligence. The company utilizes a proprietary deep-learning algorithm to enhance the design and development of proteins and enzymes, enabling the rapid prediction of high-value food products. This innovative approach allows Protera to address ethical, environmental, and consumer health challenges while producing ingredients that are both healthy and sustainably sourced. By streamlining the protein design process, Protera supports customers in bringing safe and nutritious foods to market more efficiently and cost-effectively.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Comet Biorefining, Inc. is based in London, Canada, and specializes in the development of sustainable ingredients from agricultural waste materials. The company focuses on converting non-food sources such as wood, wheat straw, bagasse, and corn stover into high-purity cellulosic glucose syrup. This innovative technology provides a cost-competitive alternative to traditional food-based sugar sources like corn or sugar cane, ensuring price stability and lower costs. In addition to its glucose products, Comet Biorefining offers biomass conversion and pretreatment services, along with a range of consulting services that include process development, engineering, and project development. The company is currently focused on scaling up its commercial operations and establishing partnerships within the renewable biofuels and biochemicals industries.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

Alia Therapeutics focuses on developing advanced gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools to target and correct inborn genetic errors directly within patients' cells. By utilizing these unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their source, providing healthcare professionals with the means to modify genomes effectively. Additionally, the company emphasizes safe and efficient delivery mechanisms to ensure the targeted treatment of affected cells.

Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Protera specializes in the development of functional ingredients for the food industry through protein engineering and artificial intelligence. The company utilizes a proprietary deep-learning algorithm to enhance the design and development of proteins and enzymes, enabling the rapid prediction of high-value food products. This innovative approach allows Protera to address ethical, environmental, and consumer health challenges while producing ingredients that are both healthy and sustainably sourced. By streamlining the protein design process, Protera supports customers in bringing safe and nutritious foods to market more efficiently and cost-effectively.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

PinCell is a biotechnology company dedicated to the research and development of innovative treatments for dermatological diseases, particularly those that are rare or orphan conditions. The firm's focus lies in identifying and targeting novel pathways associated with the underlying mechanisms of inflammatory and neoplastic skin disorders. By concentrating on these new therapeutic targets, PinCell aims to create effective therapies that address unmet medical needs within the field of dermatology. Through its research efforts, the company seeks to enable the discovery of new therapeutic molecules that can improve patient outcomes in skin disease management.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

Epsilen Bio Srl is a Milan-based biotechnology company focused on developing innovative therapies for patients with underserved medical conditions. Founded in December 2019, the company specializes in a transformative approach known as epigenetic silencing, which targets and stabilizes the genomic silencing of genes implicated in various pathological processes. By leveraging this platform, Epsilen Bio aims to provide healthcare professionals with new therapeutic options to address significant medical needs.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. The company specializes in biocatalysis and a cell-free synthetic biology platform to create sustainable alternatives to conventional materials such as plastics, nylons, and rubbers. EnginZyme's innovative approach focuses on biomanufacturing techniques that promote green chemistry across various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By utilizing patented cell-free technology, EnginZyme aims to replace traditional fossil-based manufacturing, thus facilitating the shift toward environmentally friendly production methods. The company has gained recognition for its contributions to sustainability, being named a Global Cleantech 100 company and recognized as a Technology Pioneer by the World Economic Forum. EnginZyme is supported by a diverse group of investors, reflecting its potential impact on addressing climate change and promoting sustainable practices in manufacturing.

Nitrase Therapeutics is a biopharmaceutical platform company focused on developing therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, the company aims to create drugs that may slow or halt the progression of this and other related neurodegenerative conditions. By leveraging its expertise in nitration, Nitrase Therapeutics seeks to explore the therapeutic potential of biochemical modifications of proteins, particularly through the identification of nitro-substrates and their involvement in various diseases. This approach positions the company to potentially expand its platform to address a broader range of medical conditions in the future.

Redx Pharma is a UK-based biotechnology company founded in 2010, specializing in drug discovery and development for oncology and fibrotic diseases. The company focuses on creating novel small molecule drugs aimed at addressing significant unmet medical needs. Its product pipeline includes several promising candidates such as RXC004, a porcupine inhibitor in Phase I clinical development for various cancers; ROCK2, targeting diabetic nephropathy and idiopathic pulmonary fibrosis; and RXC005, a reversible inhibitor of Bruton’s tyrosine kinase. Additionally, Redx Pharma collaborates with global pharmaceutical companies, including a research partnership with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through subsidiaries dedicated to oncology, anti-infectives, and immunology, generating revenue from scientific programs and research collaborations.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in developing bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on producing specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. Utilizing its Dynamic Metabolic Control technology, DMC Biotechnologies aims to enhance the efficiency and sustainability of production processes, reducing both energy consumption and resource use. This innovative approach allows for quicker development timelines and lower costs, supporting a transition towards a more sustainable economy.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.